Paul Garofolo is the Co-founder & CEO of Locus Biosciences, a clinical-stage biotechnology company focused on the development of crPhage (CRISPR-Cas3 and bacteriophage) technology for the selective removal of bacterial species across MDR/recurrent infectious diseases and microbiome indications. Located in Research Triangle Park, North Carolina, Locus is one of the leading biotechnology companies in the Triangle focused on advancing drug products into the clinic. Paul Garofolo has been a member of multiple Executive Management teams of both publicly traded multi-national corporations and successful startup opportunities. Prior to Locus Biosciences, Paul was the Chief Technology Officer for Patheon Pharmaceuticals where he led Global Operations for Patheon’s Pharmaceutical Development Services Division. One of the world leaders in Contract Manufacturing Outsourcing, his teams around the world led the development of all clinical trial materials programs for their Patheon’s clients.
The human microbiome has been proposed to form an integral part of human health and its role in disease is a part of large investigations. Furthermore, the microbiome is under evaluation as both a source of therapeutics as well as diagnostics. The current state of the science and medicine in relation to precision medicine approaches will be discussed.